Meeting
2018 ASCO Annual Meeting
A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).
Authors
Juan De La Haba
Biomedical Research Institute Maimonides.Hospital UniversitarioReina Sofia,Universidad de Cordoba, Spain.Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII. GEICAM, Spanish Breast Cancer Group, Spain, Cordoba, Spain
Juan De La Haba , Angel Guerrero-Zotano , Jose Alejandro Perez-Fidalgo , Santiago Gonzalez Santiago , Montserrat Muñoz , Raquel Andres , Cristina Cruz Zambrano , Sebastian Moran Salama , Sara Lopez-Tarruella , Vanesa Quiroga Garcia , Sonia Servitja , Mireia Mele , Sonia Alonso Soler , Barbara Adamo , Maria Jose Escudero , Nuria Martin , Susana Bezares , Rosalia Caballero , Manel Esteller , Federico Rojo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
NCT03205761
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS1114)
DOI
10.1200/JCO.2018.36.15_suppl.TPS1114
Abstract #
TPS1114
Poster Bd #
188a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
First Author: Navid Hafez
Poster
2024 ASCO Genitourinary Cancers Symposium
SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline BRCA1/2 mutations.
First Author: Heather H. Cheng
Poster
2023 ASCO Annual Meeting
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.
First Author: Vincent Chung
Poster
2023 ASCO Annual Meeting
Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.
First Author: Kim Anna Reiss